RANBP2 like and GRIP domain containing 8Genealiases: RANBP2L1 · RGP8 · RanBP2alpha
Q-omics provides the consensus-scored RGPD8 profile across patient tissues and cancer cell-line models. RGPD8 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RGPD8 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, RGPD8 RNA expression shows 18,929 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, BRCA, and THYM as cancer lineages where RGPD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGPD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGPD8 survival associations across molecular data types. RGPD8 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGPD8 RNA expression–survival associations across cancer types. High RGPD8 expression shows unfavorable associations in MESO, THCA and LGG, but favorable associations in UCS, LUAD and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify MESO as the clearest survival context for RGPD8 RNA expression.
This table summarizes RGPD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RGPD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGPD8 shows lower tumor expression in BRCA, KICH, THCA, LUSC, LUAD and UCEC. The BRCA box plot shows higher RGPD8 RNA expression in normal versus tumor tissue (log2 FC = −0.391, t-test p < 0.001).
This table shows molecular features associated with RGPD8 in patient tissues and cancer cell lines. In patient samples, RGPD8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGPD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
